Patient who received custom gene therapy likely died from immune reaction, not CRISPR, paper says

Researchers believe that Terry Horgan, a 27-year-old man with Duchenne muscular dystrophy who was the first person to receive a designer CRISPR therapy, died from an immune reaction likely related to the high dose of viral vector used to deliver the therapy.

A preprint paper published Wednesday described findings from Terry’s autopsy, following months of uncertainty around what exactly led to his death in October just eight days after he received the treatment. The researchers concluded that Terry’s death was not likely related to gene editing, since there was only a small signal of the CRISPR expression in the liver, and none in other organs.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

Patient who received custom gene therapy likely died from immune reaction, not CRISPR, paper says

Lei Lei Wu

News Reporter

Ryan Cross

Senior Science Correspondent

To read Endpoints News become a free subscriber

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

After gene therapy deaths, Astellas to revisit fatal neuromuscular condition in partnership with biotech startup

Upstream Bio matches first funding round with another $200M to get asthma drug to PhIII

4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients

FDA commissioner says drug prices are too high, calls for better evidence generation

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

Pa­tient who re­ceived cus­tom gene ther­a­py like­ly died from im­mune re­ac­tion, not CRISPR, pa­per says

News Reporter

Senior Science Correspondent

To read Endpoints News become a free subscriber

Patient who received custom gene therapy likely died from immune reaction, not CRISPR, paper says